Chad Decker co-founded Alphazyme in 2018 as Chief Operating Officer and has been instrumental in building the company from its inception and key in managing its acquisition by Maravai in 2023. With over 20 years of experience in commercial and operational leadership roles across biotech, healthcare, life science, and diagnostics industries, Mr. Decker has built global organizations from the ground up, efficiently integrated new acquisitions, developed strategies for aligning multiple business units and launching disruptive technologies, and had full P&L oversight. Prior to founding Alphazyme, Mr. Decker served as Chief Commercial Officer of TwinStrand Biosciences after heading commercial operations for Quad Technologies, overseeing their successful exit to Bio-Techne. Previously, he led the Qiagen Custom and OEM businesses as their Vice President of Sales and served in roles of increasing responsibility at ThermoFisher Scientific, ultimately leading the global healthcare sourcing initiative worth over $100 million. Mr. Decker holds a BS in biochemistry from Muhlenberg College.